Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination.

Goldhaber-Fiebert JD, Stout NK, Ortendahl J, Kuntz KM, Goldie SJ, Salomon JA.

Popul Health Metr. 2007 Oct 29;5:11.

4.

Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force.

Whitlock EP, Vesco KK, Eder M, Lin JS, Senger CA, Burda BU.

Ann Intern Med. 2011 Nov 15;155(10):687-97, W214-5. doi: 10.7326/0003-4819-155-10-201111150-00376. Epub 2011 Oct 17. Review. Erratum in: Ann Intern Med. 2012 Jan 3;156(1 Pt 1):71-2.

PMID:
22006930
5.

Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.

Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, Koliopoulos G, Naucler P, Sankaranarayanan R, Peto J.

Vaccine. 2012 Nov 20;30 Suppl 5:F88-99. doi: 10.1016/j.vaccine.2012.06.095. Review. Erratum in: Vaccine. 2013 Dec 16;31(52):6266.

PMID:
23199969
6.

Human papillomavirus testing in the prevention of cervical cancer.

Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE.

J Natl Cancer Inst. 2011 Mar 2;103(5):368-83. doi: 10.1093/jnci/djq562. Epub 2011 Jan 31. Review.

7.

Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials.

Rambout L, Hopkins L, Hutton B, Fergusson D.

CMAJ. 2007 Aug 28;177(5):469-79. Epub 2007 Aug 1. Review.

8.

What's next? Perspectives and future needs of cervical screening in Europe in the era of molecular testing and vaccination.

Lynge E, Antilla A, Arbyn M, Segnan N, Ronco G.

Eur J Cancer. 2009 Oct;45(15):2714-21. doi: 10.1016/j.ejca.2009.07.024. Epub 2009 Aug 18. Review.

PMID:
19695870
9.

The impact of human papillomavirus vaccination on cervical cancer prevention efforts.

Massad LS, Einstein M, Myers E, Wheeler CM, Wentzensen N, Solomon D.

Gynecol Oncol. 2009 Aug;114(2):360-4. doi: 10.1016/j.ygyno.2009.04.005. Epub 2009 May 1. Review.

10.

Human papillomavirus vaccination in adolescence.

Russell M, Raheja V, Jaiyesimi R.

Perspect Public Health. 2013 Nov;133(6):320-4. doi: 10.1177/1757913913499091. Epub 2013 Sep 4. Review.

PMID:
24006173
11.

Modeling cervical cancer prevention in developed countries.

Kim JJ, Brisson M, Edmunds WJ, Goldie SJ.

Vaccine. 2008 Aug 19;26 Suppl 10:K76-86. doi: 10.1016/j.vaccine.2008.06.009. Review.

12.

Mechanisms and predictors of high-risk human papillomavirus (HPV) clearance in the uterine cervix.

Syrjänen K.

Eur J Gynaecol Oncol. 2007;28(5):337-51. Review.

PMID:
17966211
13.

Development of a quality framework for models of cervical screening and its application to evaluations of the cost-effectiveness of HPV vaccination in developed countries.

Simonella L, Canfell K.

Vaccine. 2015 Jan 1;33(1):34-51. doi: 10.1016/j.vaccine.2014.08.048. Epub 2014 Aug 27. Review.

PMID:
25171843
14.

Cost-effectiveness of screening high-risk HIV-positive men who have sex with men (MSM) and HIV-positive women for anal cancer.

Czoski-Murray C, Karnon J, Jones R, Smith K, Kinghorn G.

Health Technol Assess. 2010 Nov;14(53):iii-iv, ix-x, 1-101. doi: 10.3310/hta14530. Review.

15.

Validation and calibration of structural models that combine information from multiple sources.

Dahabreh IJ, Wong JB, Trikalinos TA.

Expert Rev Pharmacoecon Outcomes Res. 2017 Feb;17(1):27-37. doi: 10.1080/14737167.2017.1277143. Review.

PMID:
28043174

Supplemental Content

Support Center